secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2022-09-26T23:59:59+00:00
Accession:  0001493152-22-026802
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte appoints James Liu as Controller & Principal Accounting Officer
------------------------------------------------------------------------

- James Liu, 27, appointed Controller & Principal Accounting Officer effective Sept 20, 2022.
- Liu previously served as Interim Controller since July 2022 and as Manager of SEC Reporting & Compliance.
- Annual salary of $175,000; eligible for discretionary annual bonus with target of 30% of base salary.
- Receives one-time grant of 75,000 stock options vesting 25% after 1 year, then monthly over 3 years.
- No family relationships or related party transactions with the company's directors or officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222026802/0001493152-22-026802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222026802/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-026802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer